- Conditions
- HIV Infections
- Interventions
- Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,570 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 375
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 30 Days to 18 Years
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 29
- States / cities
- Alhambra, California • Long Beach, California • Los Angeles, California + 22 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Reyataz + Norvir + Truvada, Reyataz + Epzicom
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 44
- States / cities
- Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- EVG/COBI/FTC/TDF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 7
- States / cities
- Oakland, California • Tampa, Florida • Chicago, Illinois + 4 more
- Conditions
- ART, HIV
- Interventions
- Biktarvy
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infection
- Interventions
- PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
- Behavioral · Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 15 Years to 17 Years · Male only
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
- Drug
- Lead sponsor
- Quest Clinical Research
- Other
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infections, Obesity
- Interventions
- Biktarvy, Symtuza
- Drug
- Lead sponsor
- East Carolina University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Healthy Volunteers
- Interventions
- [11c] LAAM, Ritonavir, Efavirenz
- Radiation · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC), Serous Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Interventions
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- HIV Infections
- Interventions
- Lopinavir/Ritonavir, Emtricitabine, Stavudine
- Drug
- Lead sponsor
- Triangle Pharmaceuticals
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
- Conditions
- Chronic Hepatitis B
- Interventions
- Tenofovir DF, FTC, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 6 more
- Conditions
- Osteosarcoma
- Interventions
- 18-F FTC 146
- Drug
- Lead sponsor
- Davidzon, Guido, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Multiple Sclerosis
- Interventions
- Truvada (tenofovir/emtricitabine)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Bictegravir/emtricitabine/tenofovir alafenamide, Dolutegravir, MK4646
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Anniston, Alabama
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 687 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
- Conditions
- HIV Infection
- Interventions
- Not listed
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- Female only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- HIV Prevention
- Interventions
- Descovy
- Drug
- Lead sponsor
- Vivent Health
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
- Conditions
- Human Immunodeficiency Virus Type 1
- Interventions
- TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs)
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 9
- States / cities
- Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more
- Conditions
- HIV-1-infection
- Interventions
- ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more
- Conditions
- HIV Infections
- Interventions
- Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 1,219 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hiv, Hormone Therapy
- Interventions
- Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg, Emtricitabine Tenofovir Alafenamide 200/25 mg
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Human Immunodeficiency Virus Type 1
- Interventions
- D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more